Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.43%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.29 per share when it actually produced a loss of $0.37, delivering a surprise of -27.59%. Over the last four quarters, t ...